Introduction
============

Matrine (Mat) is one of the main active ingredients of Chinese herbal medicine ([@b1-ol-0-0-5150]), such as *Sophora alopecuroides, Sophora tonkinensis*, and Radix Sophorae Flavescentis. Its pharmacological effects are quite extensive. Previous studies have focused on Mat in depth and its antitumor effect. It was previously identified that Mat is capable of inhibiting tumor cell proliferation and inducing apoptosis ([@b1-ol-0-0-5150]). It can also inhibit tumor angiogenesis, invasion, and metastasis as well as reverse tumor cell resistance to pharmacological agents. In addition, combined medication can enhance its efficacy ([@b2-ol-0-0-5150]). A large body of studies worldwide has reported that Mat treatment results in different degrees of inhibition on melanoma, lung, gastric, breast, ovarian and bladder cancers as well as others ([@b3-ol-0-0-5150]--[@b9-ol-0-0-5150]). However, studies on the effects of Mat on rhabdomyosarcoma (RMS), as well as those on the combined effects of Mat with other chemotherapeutic drugs on RMS are limited. The present study examined cisplatin, a chemotherapeutic drug commonly used to treat clinical cases of RMS, and whether its effectiveness can be improved when used in combination with Mat, to produce an antitumor effect.

X-linked inhibitor of apoptosis protein (XIAP) is a new member of the IAP family and one of the most powerful inhibitors of apoptosis ([@b10-ol-0-0-5150],[@b11-ol-0-0-5150]). At present, XIAP has been shown to be a protein of universal expression. It is expressed in various human tissues ([@b12-ol-0-0-5150],[@b13-ol-0-0-5150]), but at low levels in normal cells and is increased in cancer cells ([@b14-ol-0-0-5150]--[@b16-ol-0-0-5150]). XIAP can inhibit tumor cell apoptosis and reduce tumor cell sensitivity, such as in ovarian cancer, glioma, prostate cancer, rectal cancer and childhood acute leukemia cells ([@b17-ol-0-0-5150]--[@b20-ol-0-0-5150]). However, to the best of our knowledge, there are few relevant studies reporting its role in children\'s RMS.

In the present study, XIAP was used as a reporter to examine the effect of Mat combined with cisplatin on human RMS cells, in order to identify a new option for the clinical treatment of RMS.

Materials and methods
=====================

### Reagents

The RMS RD cell line was purchased from the Chinese Academy of Sciences Cell Bank (Shanghai, China). Mat (purity ≥98%) was purchased from Shaanxi Zhongxin Biotechnology Co., Ltd. (Shaanxi, China); the methyl hiazolyl tetrazolium (MTT) assay was purchased from Sigma (St. Louis, MO, USA); the flow cytometry kit (Annexin V-FITC kit) was purchased from Beijing Biosea Biotechnology Co., Ltd. (Beijing, China); and the total RNA extraction kit, and reverse transcription (RT)-PCR two-step kit were purchased from Tiangen Biotech (Beijing) Co., Ltd. (Beijing, China). The PCR primers were designed and produced by Sangon Biotech Co., Ltd. (Shanghai, China).

### Cell culture

RD cells were grown in RPMI-1640 supplemented with 100 g/l fetal bovine serum and 10 g/l penicillin/streptomycin and maintained in a constant temperature incubator at 37°C, and 50 ml/l CO~2~. The medium was changed once every 3--4 days, and cells were passaged once every 5--7 days. The cells were collected and used during the logarithmic phase of growth for all the experiments.

### Experimental grouping and treatments

Grouping and treatments used were: i) Control group, only RMS RD cells, without any other processing; ii) 5 mg/l cisplatin group, 5 mg/l cisplatin was added to RD cells and processed for 16 h; iii) 0.5 g/l Mat group, 0.5 g/l Mat was added to RD cells and processed for 24 h; iv) 1.0 g/l Mat group, 1.0 g/l Mat was added to RD cells and processed for 24 h; v) 1.5 g/l Mat group, 1.5 g/l Mat was added to RD cells and processed for 24 h; vi) 0.5 g/l Mat combined with cisplatin group, 0.5 g/l Mat was added to RD cells and processed for 24 h, followed by the addition of 5 mg/l cisplatin and processed for 16 h; vii) 1.0 g/l Mat combined with cisplatin group, 1.0 g/l Mat was added to RD cells and processed for 24 h, followed by the addition of 5 mg/l cisplatin and processed for 16 h; and viii) 1.5 g/l Mat combined with cisplatin group, 1.5 g/l Mat was added to RD cells and processed for 24 h, followed by the addition of 5 mg/l cisplatin and processed for 16 h.

### MTT detection of RD cell proliferation inhibitory rate

RD cells were collected in the logarithmic phase of growth, and adjusted to a concentration of 1×10^5^/l. The cell suspension (100 µl) was then inoculated into appropriate wells of a 96-well plate. Five repeats of each condition were prepared. After the cells were allowed to adhere to the plate for 24 h, they were treated in accordance with the above groupings. After 24 h, the assay was performed as previously described ([@b21-ol-0-0-5150]). Absorbance of each group was taken at 570 nm using a microplate reader (Bio-Rad, Hercules, CA, USA), and the cell proliferation inhibition rate of each group was calculated. The experiment was repeated three times.

### Flow cytometry mediated detection of RD cell apoptotic rate

RD cells were collected in the logarithmic phase and adjusted to a concentration of 1×10^5^/l. The cells were subsequently inoculated into 6-well plates, with each well containing 2 ml RPMI-1640 medium. After the cells were allowed to adhere to the plate, they were treated in accordance with the above groupings. After 24 h, the apoptotic rate of each group was assessed using an Annexin V-FITC kit according to the manufacturer\'s instructions. The experiment was repeated three times.

### RT-PCR detection of XIAP mRNA

Total RNA extraction was then carried out. Briefly, harvested cells in suspension were adjusted to a concentration of 1×10^6^/l, and inoculated into cell culture flasks. The cells were then treated in accordance with the above groupings. After 24 h, the cells were collected again and total RNA was extracted. Subsequently, 5 µl of RNA was added to 2% agarose gel for electrophoresis for detection of its quality, and the RNA concentration and purity were detected using ultraviolet spectrophotometry using GeneQuant Pro (Amersham Biosciences, Little Chalfont, UK). RT was then performed. For PCR amplification, XIAP primer sequences and internal reference sequences (GAPDH) were identified ([Table I](#tI-ol-0-0-5150){ref-type="table"}). Amplification conditions used were: Pre-degenerated under 94°C for 2 min, degenerated under 94°C for 30 sec, annealed under 55°C for 45 sec, extended under 72°C for 30 sec, for a total 32 cycles, and then extended under 72°C for 10 min. This was followed by agarose gel electrophoresis on the amplification products. The ImageJ software (National Institutes of Health, Bethesda, Maryland, USA) was used to analyze the gray level of the bands after electrophoresis, and the gene expression levels were calculated by the ratio of target gene to the level of the internal amplification product. The experiment was repeated three times.

### Statistical analysis

SPSS 16.0 statistical software (Chicago, IL, USA) was used for statistical analysis. Data were presented as mean ± standard deviation (SD). A normality and homogeneity test of variance was performed on the experimental data and variance analysis of two-factor factorial design was applied to make comparisons among groups. The Student-Newman-Keuls q-test was used in performing pairwise comparison. P\<0.05 was considered to be statistically significant.

Results
=======

### Mat and cisplatin act synergistically to inhibit the proliferation of RD cells

Using an MTT assay, it was observed that the proliferation of RD cells in each experimental group was inhibited to different degrees, compared with the control group. As the drug concentration increased, the proliferation inhibition effect was gradually increased (P\<0.05). The proliferation inhibition rate of Mat combined with the cisplatin groups was significantly higher than those of the single Mat and single cisplatin groups under the same concentration (P\<0.01). These data suggested that Mat and cisplatin act synergistically to inhibit the proliferation of RD cells ([Table II](#tII-ol-0-0-5150){ref-type="table"} and [Fig. 1](#f1-ol-0-0-5150){ref-type="fig"}).

### Mat and cisplatin act cooperatively to induce apoptosis of RD cells

Flow cytometry results showed that, compared with the control group, the apoptotic rate of RD cells in each experimental group was increased to varying degrees (P\<0.05). An increase in drug concentration, led to the apoptotic rate of RD cells in single Mat groups being gradually increased (P\<0.05). The apoptotic rate of Mat combined with the cisplatin groups was significantly higher than those of the single cisplatin and single Mat groups under the same concentration (P\<0.05). Consistent with the observation on the inhibition of cell proliferation, Mat and cisplatin acted cooperatively to induce the apoptosis of RD cells ([Table II](#tII-ol-0-0-5150){ref-type="table"}; [Figs. 2](#f2-ol-0-0-5150){ref-type="fig"} and [3](#f3-ol-0-0-5150){ref-type="fig"}).

### Mat and cisplatin act synergistically to reduce the XIAP mRNA expression levels

XIAP mRNA was expressed in cells of the control and each experimental group. The expression levels of XIAP mRNA in RD cells of each experimental group were lower than those in the control group (P\<0.05). Compared with the single cisplatin group, the expression levels of XIAP mRNA in Mat combined with the cisplatin group were significantly reduced (P\<0.05). Compared with the single Mat groups under the same concentration, the expression levels of XIAP mRNA in the Mat combined with cisplatin group were significantly reduced (P\<0.01). These data showed that Mat and cisplatin act synergistically to reduce the expression levels of XIAP mRNA ([Table II](#tII-ol-0-0-5150){ref-type="table"}; [Figs. 4](#f4-ol-0-0-5150){ref-type="fig"} and [5](#f5-ol-0-0-5150){ref-type="fig"}).

Discussion
==========

RMS is the most common soft tissue sarcoma in children, accounting for 4--8% of all malignant pediatric solid tumors ([@b22-ol-0-0-5150]), and 53% of soft tissue sarcomas ([@b23-ol-0-0-5150]). RMS can appear in any part of the body. It is most commonly seen in the head and neck of children and is characterized by high malignancy and rapid progression ([@b24-ol-0-0-5150]). It is challenging to diagnose the disease in its early stages. When patients arrive under hospital care, the disease is at an advanced stage and the tumor cannot be removed by surgery. At this point, comprehensive therapy by combining surgery with chemo- and radiotherapy should be utilized. Drug resistance to chemotherapy often results in treatment failure. Therefore, the need to improve the curative effect of chemotherapy drugs, and reverse the drug resistance of tumor cells has become a research hotspot.

In recent years, the traditional Chinese medicine, Mat, has increasingly aroused the interest of scholars due to its physicochemical properties of low toxicity and high efficacy. Previous findings have shown that Mat had a significant inhibitory effect on a variety of tumor cells, such as neuroblastoma, medulloblastoma, colorectal cancer, nasopharyngeal carcinoma, leukemia cells and RMS ([@b25-ol-0-0-5150]--[@b31-ol-0-0-5150]). In addition, the antitumor mechanism of Mat mainly included obstructing tumor cell cycle progression, inhibiting tumor cell proliferation, inducing tumor cell apoptosis and reversing chemotherapy drug resistance ([@b32-ol-0-0-5150]).

Guo *et al* ([@b33-ol-0-0-5150]) and Li *et al* ([@b34-ol-0-0-5150]) investigated the 24 and 48 h effects of different concentrations of Mat on RMS. The results have confirmed that Mat inhibited the proliferation of RMS, inducing cell apoptosis and maintaining the cell cycle in the G0/G1 phase. The results of the present study have shown that the proliferation inhibition rate and apoptosis rate of RD cells treated at different concentrations of Mat (0.5, 1.0 and 1.5 g/l) were higher than those in the control group. Additionally, as the concentration of Mat increased, the apoptosis rate of RD cells also increased, confirming that Mat suppressed the proliferation and induced the apoptosis of RMS cells. The effect was dose-dependent to a certain degree. Our experimental results were consistent with those of Guo *et al* and Li *et al* ([@b33-ol-0-0-5150],[@b34-ol-0-0-5150]).

Thanks to its broad anticancer properties, cisplatin has occupied an extremely significant and unique position in the field of cancer treatment since 1970 ([@b35-ol-0-0-5150]). It is commonly regarded as an anticancer drug with epoch-making significance, particularly effective for urogenital tumors and malignant carcinomas of the neck ([@b35-ol-0-0-5150]). However, as the use of cisplatin became increasingly widespread, it became apparent that it had toxic side effects while killing cancer cells and that most of these side effects were related to the dose of cisplatin. The toxic side effects of cisplatin mainly manifested as a result of its application in the clinic. However, approaches regarding how to reduce the toxicity and side effects of cisplatin have become an area of interest in clinical research. Further studies on cisplatin revealed that it had synergistic effects with multiple other drugs. Drug combinations can enhance their antitumor effects, reduce the required dose of cisplatin, and reduce the toxic side effect of cisplatin. Sárosi and Lénárt showed that the combination of gemcitabine and cisplatin was effective in the treatment of advanced non-small cell lung cancer, and that the side effects were relatively minor ([@b36-ol-0-0-5150]). Solár *et al* have shown that geldanamycin enhanced the cytotoxic effect of cisplatin on tumor cells ([@b37-ol-0-0-5150]).

In recent years, as research on the antitumor effects of Chinese medicine progressed, investigators examined how to enhance the anticancer effect of antitumor drugs while lowering their toxicity and side effects. Several studies have shown that rhubarb, bufalin, *Radix Astragali*, Shengmai, Mat and other traditional Chinese medicines may enhance the anticancer effects of cisplatin to varying degrees ([@b38-ol-0-0-5150]--[@b41-ol-0-0-5150]). However, to the best of our knowledge, few studies focused on the effects of Mat combined with cisplatin on RMS. In the present study, we used Mat at different concentration (final concentrations were 0.5, 1.0 and 1.5 g/l) in combination with cisplatin (final concentration was 5 mg/l) to treat RMS RD cells cultured *in vitro*. We then used the MTT assay, flow cytometry and RT-PCR to measure the effects on proliferation inhibition and apoptosis of RD cells. The results of the present study show that the proliferation inhibition rate and apoptosis rate of RD cells in Mat (different concentrations) combined with cisplatin groups was significantly higher than that in the single Mat or cisplatin groups. Our study also confirmed that Mat and cisplatin produced a synergistic effect, and that the combination therapy can significantly kill RMS RD cells.

In recent years, with the extensive clinical application of cisplatin, the phenomenon of cisplatin resistance has become increasingly widespread, which has generated interest among scholars to explore the mechanisms of drug resistance. Amantana *et al* have shown that DU145 prostate cancer cells were resistant to cisplatin and that high expression levels of XIAP were a cause of DU145 resistance to cisplatin. The study also confirmed that antisense nucleic acid therapy of XIAP can enhance the antitumor effect of cisplatin and increase the sensitivity of the DU145 cell line to cisplatin ([@b42-ol-0-0-5150]). XIAP is a new member of the IAPs family and also one of the most powerful inhibitors of apoptosis ([@b23-ol-0-0-5150],[@b24-ol-0-0-5150]). At present, XIAP has been shown to be a protein of universal expression. It is expressed in various human tissues ([@b25-ol-0-0-5150],[@b26-ol-0-0-5150]), but at low levels in normal tissue cells and is increased in cancer cells ([@b27-ol-0-0-5150]--[@b29-ol-0-0-5150]). We have studied the effects of different concentrations of Mat in combination with cisplatin on the expression of XIAP in human RMS RD cells using RT-PCR analysis. The results showed that XIAP was expressed in RMS RD cells. Following treatment with Mat and/or cisplatin, the expression levels of XIAP in the cells were decreased. In the dose-response experiments, XIAP mRNA decreased as a function of increasing Mat concentration. The expression of XIAP mRNA was significantly reduced under the combined effect of Mat and cisplatin versus Mat or cisplatin alone.

In conclusion, our experimental results show that Mat combined with cisplatin inhibited the expression of XIAP in RMS RD cells and induced apoptosis in these tumor cells. The results also indicate that Mat may lower the tolerance of RMS RD cells to cisplatin by inhibiting the expression of XIAP, thus improving the curative effect of cisplatin. We believe this study reveals a potential new target for the study of drug-resistant RMS cell lines and may also lead to new therapeutic options for the clinical treatment of RMS.

![Interaction effect sketch map (proliferation inhibition rate of RD cells). The green line is the inhibitory rate of cell proliferation in the Mat group combined with cisplatin at different concentrations. The blue line is the inhibitory rate of cell proliferation in the Mat monotherapy group at different concentrations. Mat, matrine.](ol-12-05-3793-g00){#f1-ol-0-0-5150}

![Flow cytometry mediated detection of apoptosis of RD cells. (A) Positive control group, (B) 5 mg/l cisplatin group, (C) 0.5 g/l Mat group, (D) 1.0 g/l Mat group, (E) 1.5 g/l Mat group, (F) 0.5 g/l matrine combined with cisplatin group, (G) 1.0 g/l Mat combined with cisplatin group, (H) 1.5 g/l Mat combined with 5 mg/l cisplatin group. The upper left quadrant (Q1) shows cells under mechanical injury (Annexin V^−^/PI^+^); upper right quadrant (Q2) shows cells under advanced apoptosis and secondary necrosis (Annexin V^+^/PI^+^); lower left quadrant (Q4) shows surviving cells (Annexin V^−^/PI^−^); lower right quadrant shows cells undergoing early apoptosis (Annexin V^+^/PI^−^). Mat, matrine.](ol-12-05-3793-g01){#f2-ol-0-0-5150}

![Interaction effect sketch map (apoptosis rate of RD cells). The green line is the cell apoptosis rate in the Mat group combined with cisplatin at different concentrations. The blue line is the cell apoptotic rate in the Mat monotherapy group at different concentrations. Mat, matrine.](ol-12-05-3793-g02){#f3-ol-0-0-5150}

![Interaction effect sketch map (the expression level of XIAP in RD cells). The green line is the expression level of XIAP in the Mat group combined with cisplatin at different concentrations. The blue line is the expression level of XIAP in the Mat monotherapy group at different concentrations. Mat, matrine; XIAP, X-linked inhibitor of apoptosis protein.](ol-12-05-3793-g03){#f4-ol-0-0-5150}

![XIAP mRNA expression in each group of RD cells. The upper band is the internal reference (GAPDH). The lower band is the target band (XIAP). Lane 1, control group; lane 2, 0.5 g/l Mat group; lane 3, 1.0 g/l Mat group; lane 4, 1.5 g/l Mat group; lane 5, mg/l cisplatin group; lane 6, 0.5 g/l Mat combined with cisplatin group; lane 7, 1.0 g/l Mat combined with cisplatin group; and lane 8, 1.5 g/l Mat combined with cisplatin group. XIAP, X-linked inhibitor of apoptosis protein; Mat, matrine.](ol-12-05-3793-g04){#f5-ol-0-0-5150}

###### 

Primer sequence and annealing temperature of the XIAP and reference genes.

  Gene      Primer (5′→3′)   PCR amplification products size (bp)   Annealing temperature (°C)   
  --------- ---------------- -------------------------------------- ---------------------------- ----
  *XIAP*    Sense:           ATGGGATTTGATTTCAAGGA                   256                          55
            Antisense:       GTCCACAAGGAATAAAAACA                                                
  *GAPDH*   Sense:           ACCACAGTCCATGCCATCAC                   452                          55
            Antisense:       TCCACCACCCTGTTGCTGTA                                                

XIAP, X-linked inhibitor of apoptosis protein.

###### 

Proliferation inhibition rate, apoptosis rate and XIAP mRNA expression level (n=3, mean ± SD) of each group.

  Group             Proliferation inhibition rate (%)                                                                                                                 Apoptosis rate (%)                                                                                                                                XIAP expression (FI)
  ----------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Control           7.60±6.22                                                                                                                                         7.80±0.85                                                                                                                                         0.90±0.57
  Cisplatin         29.83±1.60^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"}^                                                                                           22.33±0.97^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"}^                                                                                           0.36±0.04^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"}^
  Mat                                                                                                                                                                                                                                                                                                                   
    0.5 g/l         15.93±2.50^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"}^                                                                                           12.63±0.85^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"}^                                                                                           0.67±0.06^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"}^
    1.0 g/l         23.20±2.33^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [b](#tfn3-ol-0-0-5150){ref-type="table-fn"}^                                             16.93±0.81^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [b](#tfn3-ol-0-0-5150){ref-type="table-fn"}^                                             0.50±0.03^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [b](#tfn3-ol-0-0-5150){ref-type="table-fn"}^
    1.5 g/l         36.73±2.48^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [b](#tfn3-ol-0-0-5150){ref-type="table-fn"}^                                             27.63±0.70^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [b](#tfn3-ol-0-0-5150){ref-type="table-fn"}^                                             0.28±0.04^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [b](#tfn3-ol-0-0-5150){ref-type="table-fn"}^
  Mat + cisplatin                                                                                                                                                                                                                                                                                                       
    0.5 g/l         46.00±1.45^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [c](#tfn4-ol-0-0-5150){ref-type="table-fn"}^                                             36.47±3.00^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [c](#tfn4-ol-0-0-5150){ref-type="table-fn"}^                                             0.21±0.02^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},\ [c](#tfn4-ol-0-0-5150){ref-type="table-fn"}^
    1.0 g/l         56.27±2.24^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},[c](#tfn4-ol-0-0-5150){ref-type="table-fn"},[d](#tfn5-ol-0-0-5150){ref-type="table-fn"}^   44.03±2.06^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},[c](#tfn4-ol-0-0-5150){ref-type="table-fn"},[d](#tfn5-ol-0-0-5150){ref-type="table-fn"}^   0.14±0.02^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},[c](#tfn4-ol-0-0-5150){ref-type="table-fn"},[d](#tfn5-ol-0-0-5150){ref-type="table-fn"}^
    1.5 g/l         68.83±1.35^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},[c](#tfn4-ol-0-0-5150){ref-type="table-fn"},[d](#tfn5-ol-0-0-5150){ref-type="table-fn"}^   69.00±5.48^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},[c](#tfn4-ol-0-0-5150){ref-type="table-fn"},[d](#tfn5-ol-0-0-5150){ref-type="table-fn"}^   0.07±0.03^[a](#tfn2-ol-0-0-5150){ref-type="table-fn"},[c](#tfn4-ol-0-0-5150){ref-type="table-fn"},[d](#tfn5-ol-0-0-5150){ref-type="table-fn"}^
  F-value           141.581                                                                                                                                           203.905                                                                                                                                           162.600
  P-value           0.01                                                                                                                                              \<0.0001                                                                                                                                          \<0.0001

Comparison with the control group;

comparison with the 0.5 g/l Mat group;

comparison with 0.5 g/l Mat combined with the cisplatin group; P\<0.05.

Comparison between the Mat group and Mat combined with cisplatin at different concentrations were statically significant (P\<0.05). Mat, matrine; XIAP, X-linked inhibitor of apoptosis protein.
